Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.32 |
| ▸ | TTR known ✓ | P02766 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | WRN | Q14191 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | WNT3 | P56703 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL562710 | 1.00 | LMNA (0.34) | LMNAVCPBACE1BACE2ALDH1A1 | |
| SCHEMBL444454 | 0.98 | LMNA (0.34) | LMNAVCPBACE1BACE2ALDH1A1 | |
| SCHEMBL27627029 | 0.93 | EPHX1 (0.34) | LMNAVCPBACE1BACE2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL30949078 | 0.89 | F11 (0.34) | LMNAVCPBACE1BACE2TTR | |
| SCHEMBL15935489 | 0.87 | LMNA (0.33) | LMNABACE1BACE2ALDH1A1CYP1A2 | |
| SCHEMBL12092098 | 0.83 | LMNA (0.47) | LMNAALDH1A1CYP1A2HPGDCYP2C19 | |
| Hydrochloric Acid SCHEMBL20485118 | 0.82 | TTR (0.36) | LMNAALDH1A1HPGDCYP2C19WNT3 | |
| Hydrochloric Acid SCHEMBL25415692 | 0.81 | LMNA (0.44) | LMNAVCPBACE1BACE2ALDH1A1 | |
| SCHEMBL744123 | 0.81 | SMN1; SMN2 (0.37) | BACE1BACE2ALDH1A1CYP1A2HPGD | |
| SCHEMBL16072051 | 0.81 | SMN1; SMN2 (0.37) | BACE1BACE2ALDH1A1CYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190017959-A1 | CHEMICALLY-SENSITIVE SENSOR ARRAY CALIBRATION CIRCUITRY | ION TORRENT SYSTEMS INCORPORATED | 2019-01-17 | — | — | US | disclosed |
| US-9927393-B2 | Methods and apparatus for measuring analytes | Life Technologies Corporation (US) | 2018-03-27 | — | — | US | disclosed |
| US-20180000906-A1 | MULTILAMELLAR LIPID VESICLE COMPOSITIONS INCLUDING A CONJUGATED ANAPLASTIC LYMPHOMA KINASE (ALK) VARIANT AND USES THEREOF | VEDANTRA PHARMACEUTICALS, INC. (US) | 2018-01-04 | — | — | US | disclosed |
| US-20170246288-A1 | MULTILAMELLAR LIPID VESICLE COMPOSITIONS AND METHODS OF USE | VEDANTRA PHARMACEUTICALS, INC. (US) | 2017-08-31 | — | — | US | disclosed |
| US-9616020-B2 | Lipid vesicle compositions and methods of use | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-04-11 | — | — | US | disclosed |
| US-9515676-B2 | Methods and computer program products for compression of sequencing data | Life Technologies Corporation (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160303046-A1 | LIPID VESICLE COMPOSITIONS AND METHODS OF USE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-10-20 | — | — | US | disclosed |
| US-9458502-B2 | Methods and apparatus for measuring analytes using large scale FET arrays | Life Technologies Corporation (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160061772-A1 | METHODS AND APPARATUS FOR MEASURING ANALYTES | ION TORRENT SYSTEMS INCORPORATED | 2016-03-03 | — | — | US | disclosed |
| US-9269708-B2 | Methods and apparatus for measuring analytes using large scale FET arrays | Life Technologies Corporation (US) | 2016-02-23 | — | — | US | disclosed |
| US-20110229529-A1 | LIPID VESICLE COMPOSITIONS AND METHODS OF USE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110217697-A1 | METHODS AND APPARATUS FOR MEASURING ANALYTES USING LARGE SCALE FET ARRAYS | Life Technologies Corporation (CA) | 2011-09-08 | — | — | US | disclosed |
| US-20100330155-A1 | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA | FLAGSHIP VENTURES (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100317614-A1 | COMPOSITIONS AND METHODS FOR PEST CONTROL | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100282617-A1 | METHODS AND APPARATUS FOR DETECTING MOLECULAR INTERACTIONS USING FET ARRAYS | ION TORRENT SYSTEMS INCORPORATED (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100137143-A1 | METHODS AND APPARATUS FOR MEASURING ANALYTES | ION TORRENT SYSTEMS INCORPORATED (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100035247-A1 | Heterogeneous Assay of Analytes in Solution Using Polymers | U.S. GENOMICS, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-7595160-B2 | Analyte detection using barcoded polymers | U.S. GENOMICS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090215032-A1 | ANALYTE DETECTION USING BARCODED POLYMERS | U.S. GENOMICS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20080311040-A1 | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA | FLAGSHIP VENTURES (US) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246288-A1 | MULTILAMELLAR LIPID VESICLE COMPOSITIONS AND METHODS OF USE | CHMP4B, ABCB4, VMA21 | CA2 2192/4885TTR 3387/4885LMNA 3170/4885 |
| US-20110229529-A1 | LIPID VESICLE COMPOSITIONS AND METHODS OF USE | CHMP4B, LIPA, SGMS2 | CA2 3387/4885TTR 447/4885LMNA 617/4885 |
| US-20180000906-A1 | MULTILAMELLAR LIPID VESICLE COMPOSITIONS INCLUDING A CONJUGATED ANAPLASTIC LYMPHOMA KINASE (ALK) VARIANT AND USES THEREOF | ALK, BCR, PIK3R5 | CA2 2931/4885TTR 1574/4885LMNA 3633/4885 |
| US-20080311040-A1 | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA | NSUN3, AGO2, NSUN2 | CA2 4326/4885TTR 4112/4885LMNA 1918/4885 |
| US-20100317614-A1 | COMPOSITIONS AND METHODS FOR PEST CONTROL | MANBA, ENGASE, G6PC1 | CA2 976/4885TTR 1128/4885LMNA 1534/4885 |
| US-20160303046-A1 | LIPID VESICLE COMPOSITIONS AND METHODS OF USE | CHMP4B, LIPA, SGMS2 | CA2 3387/4885TTR 447/4885LMNA 617/4885 |
| US-20100330155-A1 | METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA | NSUN3, AGO2, NSUN2 | CA2 4326/4885TTR 4112/4885LMNA 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.